U.S. Contraceptive Peer Comparison Analysis

Latest Updates of Key Players in the U.S. Contraceptive Market

Your complete U.S. Contraceptive Market control center is just one click away - Buy Now.

Supply Chain Analysis

R&D:

• Research and development (R&D) for U.S. contraceptives involves discovery and basic research, target product profile, preclinical development, clinical trials, regulatory approval, product acceptance, and manufacturing and commercialization
• Key Players: Viatris Inc. and CooperSurgical, Inc. 

Manufacturing Processes:

• Manufacturing processes for contraceptives are significantly specialized, based on whether the product is a pharmaceutical, such as pills, injections, implants, or a barrier method like condoms or diaphragms.
• Key Players: Bayer AG and Pfizer Inc.

Patient Services:

• Patient services included in contraception are comprehensive, concentrating on voluntary, informed, and client-driven care to support patients in choosing, initiating, and continuing their progress.
• Key Players: Teva Pharmaceutical Industries and Organon

Market Growth

The U.S. contraceptive market size was estimated at USD 10.8 billion in 2025 and is predicted to increase from USD 11.52 billion in 2026 to approximately USD 20.66 billion by 2035, expanding at a CAGR of 6.7% from 2026 to 2035. The U.S. contraceptive market is growing due to its support for individuals to avoid unwanted pregnancies and plan births, which lowers pregnancy-related health challenges, specifically for adolescent girls.

Recent Developments in the U.S. Contraceptive Market

• In February 2026, NEXT Life Sciences, a leader in reproductive and sexual health companies, is revolutionizing the contraceptive category with two male birth control options that meet these needs, both in active clinical trials. Non-hormonal methods at the forefront of male interest have been long-acting, reversible options and temporary, on-demand solutions.
• In January 2026, Organon, a worldwide healthcare organization with a mission to deliver impactful medicines and services for a healthier each day, announced that the US Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for NEXPLANON, which is indicated for use by women of reproductive potential to prevent pregnancy.
• In December 2025, the Center for Reproductive Rights filed a lawsuit against the U.S. Department of State for refusing to offer data related to its plans to destroy at least $10 million of unexpired, taxpayer-funded contraceptives meant for low-income countries.
• In November 2025, Femasys Inc. announced a significant initial order valued at around $500,000 USD for the profitable launch of FemBloc Permanent Birth Control in France and the Benelux region via its partnership with leading distributor Kebomed.